RT Cobie (@cobie)Probably one of the most severe flushes I’ve ever seen on alts, I didn’t even imagine alts had this much leverage in them. It feels like someone got hit very hard and will see a large body float to the surface soon, reminds me a little of summer 2021.Good reminder to myself to own things that I am actually bullish on, and not things I am trying to shift on momentum. Some charts look like they’ll never recover, whereas some things look buyable for the first time in a while.When everyone is m ...

RT Cobie (@cobie)Probably one of the most severe flushes I’ve ever seen on alts, I didn’t even imagine alts had this much leverage in them. It feels like someone got hit very hard and will see a large body float to the surface soon, reminds me a little of summer 2021.Good reminder to myself to own things that I am actually bullish on, and not things I am trying to shift on momentum. Some charts look like they’ll never recover, whereas some things look buyable for the first time in a while.When everyone is m ...

BNBHolder算是入圈以来绝对值最大的一波亏损，刚刚也给平仓了。亏损20wu+。还好交易所抄底1400的 eth 和140的 sol 回来了一些。还好自己没有任何杠杆和合约的仓位，不然一觉醒来会难受死。但是人不能指望这些『还好』，控制这些风险需要：大资金翻倍出本的习惯、不上杠杆和合约、留好现金、控制整体风险。这样别人的黑天鹅就可能会是你的机会。不要被牛市冲昏了头脑，任何时候的第一目标都是活下去要紧。XQ (@0xXQ1):还好追了龙头BNBHolder，等排行榜上 alpha。$BNBHolder 奖励 BNB Holder https://t.co/d4n9pBOGGW ...

Core Insights - The panel at Token2049 emphasized that in the volatile crypto market, sustainable success relies more on risk management than on the size of gains [3][9] Group 1: Panel Overview - The panel was moderated by Oihyun and featured experts Fenni and Dylan, who provided insights into market structure and trading strategies [2] - The discussion transitioned from showcasing successful trades to focusing on the importance of professional trading discipline [3] Group 2: Successful Trades - Fenni's best trade involved buying Ethereum (ETH) at $1,500, showcasing a strategic approach based on valuation rather than market hype [5] - Dylan highlighted profitable trades in meme coins like Pepe, but cautioned that such speculative trades are exceptions and can lead to significant risks without proper controls [6] Group 3: Risk Management Philosophy - The panel unanimously agreed that turning successful trades into a sustainable career hinges on rigorous risk management practices [7] - The central thesis presented was that trading success is fundamentally about risk management rather than individual trading views [8]

Core Insights - The biotech investment strategy focuses on a balanced portfolio with 85% in commercial stage and 15% in clinical stage companies, emphasizing disciplined position sizing and quality over quantity [5][6][8] - The community aspect of biotech investing is highlighted, where collaboration and feedback among members enhance investment decisions and strategies [9][10][15] - The current market environment presents opportunities in rare diseases and companies nearing growth stages, with a focus on those with approved drugs and clear paths to profitability [21][24][27] Group 1 - The ROTY Biotech Community has grown to nearly 500 members, including analysts and medical professionals, contributing to a collaborative investment environment [5][9] - The investment approach includes strict position sizing rules, with a maximum of 10% in commercial stage companies and 5% in clinical stage companies [6][20] - The strategy emphasizes long-term perspectives, focusing on sales projections for 2025 and beyond, and the importance of clinical momentum [8][21] Group 2 - Recent successes in the biotech sector, such as uniQure's advancements in gene therapy, have attracted more generalist investors to the space [16][18] - The investment community encourages a disciplined approach to trading, with a focus on maintaining a trade log to analyze performance and improve strategies [22][30] - The importance of understanding regulatory risks is emphasized, as even promising drugs can face unexpected challenges during the approval process [44][49] Group 3 - Syndax Pharmaceuticals is highlighted as a top holding, with a significant gain since entry, driven by positive developments in their lead drug [32][33] - Geron Corporation is presented as a potential investment opportunity, with a focus on its approved drug for blood cancer and a favorable enterprise value [49][52] - The current market dynamics suggest that while some biotech stocks are being overlooked, there are attractive opportunities in commercial stage companies [38][47]

Core Insights - Mr. Mavroudis is a professional portfolio manager with a focus on risk management and financial market analysis [1] - He has successfully navigated major crises, including the COVID-19 pandemic and the PSI [1] - Mr. Mavroudis is the CEO of FAST FINANCE Investment Services, a registered Greek company [1] Company Profile - FAST FINANCE Investment Services is registered with the Hellenic Capital Market Commission [1] - The company specializes in managing institutional and private portfolios [1] - It offers services across various financial instruments globally, including stocks, bonds, foreign exchange, and commodities [1] Professional Background - Mr. Mavroudis holds multiple degrees, including an MSc in Financial and Banking Management, an LLM in Law, and a BSc in Economics [1] - He is a certified portfolio manager and has various certifications related to financial instruments and derivatives [1] - He has published three books on investments and contributes articles to reputable financial media [1] Engagement and Community - By writing on Seeking Alpha, the company aims to engage with a community of investors and market enthusiasts [1] - The goal is to foster mutual growth and knowledge sharing within the investment community [1]

Core Insights - The article emphasizes the importance of identifying high-potential investment opportunities before they gain mainstream attention, focusing on asymmetric risk-reward scenarios [1] - The investment strategy is centered around a 4-5 year horizon, allowing for the absorption of market volatility while aiming for significant long-term returns through disciplined capital allocation [1] Investment Methodology - **Leadership & Management Analysis**: Focus on companies with proven track records in scaling, smart capital allocation, and insider ownership, alongside consistent revenue growth and credible guidance [1] - **Market Disruption & Competitive Positioning**: Target firms with strong technology moats, first-mover advantages, and network effects that facilitate exponential growth in high-growth industries [1] - **Financial Health & Risk Management**: Prioritize sustainable revenue growth, efficient cash flow, and strong balance sheets to ensure long-term survival while avoiding excessive dilution [1] - **Valuation & Asymmetric Risk/Reward**: Utilize revenue multiples compared to peers and DCF modeling to assess value, ensuring downside protection while maximizing upside potential [1] - **Portfolio Construction & Risk Control**: Maintain a diversified portfolio with core positions (50-70%), growth bets (20-40%), and speculative investments (5-10%) to balance risk and reward [1]

Hi, I'm Yiannis. Spotting winners before they break out is what I do best.Experience: Previously worked at Deloitte and KPMG in external/internal auditing and consulting. Education: Chartered Certified Accountant, Fellow Member of ACCA Global, with BSc and MSc degrees from U.K. business schools. Investment Style: Spotting high-potential winners before they break out, focusing on asymmetric opportunities (with at least upside potential of 2-3X outweighing the downside risk). By leveraging market inefficienci ...

Risk management is getting harder. But risk avoidance is not an option https://t.co/IozkZaLNGZ ...

我从来不自动开单，都是手动判断。人工去开单，宁愿错过，也不愿意在梦中被爆， ...